chinese expert consensus on high dose anti vascular endothelial growth factor therapy for neovascular age related macular degeneration 2026

Original title: “[Chinese expert consensus on high-dose anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (2026)].”

multivariable prognostic models for age related macular degeneration a systematic review

Original title: “Multivariable Prognostic Models for Age-Related Macular Degeneration: A Systematic Review.”

In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life.

Original title: “When vision fades: Rethinking wet AMD and the durability gap”

Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.

Original title: “EyePoint plummets on pivotal data for main drug”

EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.

Original title: “EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race”

The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial human therapeutic candidate is a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial ... The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial human therapeutic candidate is a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is targeted under a Cooperative Research and Development Agreement (CRADA) with the NEI. Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study Palm Beach Gardens, FL, April 15, 2026 (GLOBE... Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study · Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT, CUBTD) (“Curative” or the “Company”), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has engaged Sterling Pharmaceutical Services, LLC, a U.S.-based contract development and manufacturing organization (CDMO), to manufacture clinical supply of its metformin-based topical ophthalmic formulation. As previously disclosed, the Company is developing a metformin-based topical ophthalmic formulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). The Company is also advancing development of a K9 therapeutic candidate targeting PDE6-associated retinal degeneration, a genetic early-onset retinal disease in dogs that may provide translational insights relevant to human Retinitis Pigmentosa.

Original title: “Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply of Metformin Topical Ophthalmic Therapy”

sirna targeting s6k1 identifies photoreceptor phospholipid metabolism as a contributor to lipid buildup in age related macular degeneration

Original title: “An siRNA targeting S6k1 identifies photoreceptor phospholipid metabolism as a contributor to lipid buildup in age-related macular degeneration.”

Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and the US. The platforms encompass advanced retinal organoids and 2D retinal pigment epithelium (RPE) models designed to support preclinical research and translational drug development. Growing investment in research to discover new therapeutics for eye diseases such as age-related macular degeneration, glaucoma and rare disease has driven Axol’s strategic expansion into ophthalmology, with Phenocell previously acquiredin October 2024.

Original title: “Axol to progress eye disease treatments with new acquisition - Drug Discovery World (DDW)”

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to determine a regulatory path for Axpaxli.

Original title: “Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA”

Breakthrough modeling technology reveals how cells lose their organization in leading cause of vision loss.

Original title: “NIH scientists develop "digital twin" of eye cells to understand and treat age-related macular degeneration”